Greg Kennelty

What do patients think about being tested for many genes that may impact their hereditary risk for breast or ovarian cancer, beyond the well-known BRCA mutations?

National guidelines recommend that women with a personal history of ovarian cancer be tested for the BRCA mutation. Approximately 1.3% of women will develop ovarian cancer, according to the National Cancer Institute, but that risk increases to an estimated 39% in women with the BRCA1 mutation and 11% to 17% in women who inherit the BRCA2 mutation.

Encouraging findings for PD-1 inhibitor–based immunotherapies for the treatment of patients with metastatic head and neck cancer are emerging from clinical studies.